Alin Constantin Pînzariu, Sebastian Marian Leonte, Alexandra Gabriela Trofin, Laura Mihaela Trandafir, Mihaela Moscalu, Lorena Mihaela Manole, Roxana Moscalu, Cristina Iuliana Lazăr, Luminiţa Confederat, Vlad Ionuț Vlăsceanu, Radu Petru Soroceanu, Daniel Timofte, Nicolae Șerban Dragomir, Ionela Lăcrămioara Șerban
Obesity in the pediatric population has become a public health problem with an increasing prevalence in recent years. The gut microbiota and its metabolites, especially short-chain fatty acids (SCFAs), play vital roles in the development of pediatric obesity. This manuscript aims to highlight the link between the gut microbiota and obesity by examining microbial imbalances, such as altered Firmicutes/Bacteroidetes ratios and altered SCFA production, especially butyrate, propionate, and acetate. Advances in genomic technologies, such as 16S rRNA sequencing, have enabled personalized treatments and detailed profiling of microbial diversity. This review includes not only preclinical studies but also clinical trials of interventions, such as probiotics, synbiotics, prebiotics, and butyrate supplements. These may modify the microbiota and SCFA levels to reduce obesity and related conditions, such as metabolic syndrome and precocious puberty. Future research should focus on using advanced genomic sequencing techniques to develop new therapeutic strategies, as well as on creating a complex predictive algorithm for assessing metabolic risk in pediatric patients with obesity, an innovation that can be extended to other metabolic conditions.